pharma · Hypertension · Uncontrolled and Resistant Hypertension · MLYS
Mineralys Therapeutics
Mineralys Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Radnor, USA
- Founded
- 2020
- Employees
- 106
- Programs
- 7
- Drugs
- 6
- Patents
- 0
Mineralys Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Mineralys Therapeutics.
Mineralys Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
MLS-101-301
Mineralys Therapeutics
Uncontrolled and Resistant Hypertension
1 trial -
MLS-101-901
Mineralys Therapeutics
Hypertension
1 trial -
Placebo
Mineralys Therapeutics
Hypertension
2 trials -
lorundrostat
Mineralys Therapeutics
Hypertension
1 trial -
Lorundrostat
Mineralys Therapeutics
Obstructive Sleep Apnea
1 trial -
MLS-101 (Part I)
Mineralys Therapeutics
Hypertension, Renal
1 trial -
MLS-101-206
Mineralys Therapeutics
Chronic Kidney Disease
1 trial
Frequently asked questions
How many clinical projects does Mineralys Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.